Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3977
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTan, L. Z.en
dc.contributor.authorLewindon, P.en
dc.contributor.authorClark, J.en
dc.contributor.authorReilly, C.en
dc.contributor.authorBalouch, F.en
dc.contributor.authorBurgess, C.en
dc.date.accessioned2022-11-07T23:48:02Z-
dc.date.available2022-11-07T23:48:02Z-
dc.date.issued2021en
dc.identifier.citation72, (SUPPL 1), 2021, p. 21en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/3977-
dc.description.abstractBackground: Primary Sclerosing Cholangitis and Ulcerative colitis (PSC-UC) is an emerging phenotype, distinct from other Inflammatory Bowel Disease (IBD) with catastrophic liver and colonic outcomes, in particular higher rates of cancer and premature death. PSC-UC can prove resistant to conventional medical therapies (CMT). Oral Vancomycin Therapy (OVT) is proposed for PSC with uncertain impact on liver outcomes but recently reported efficacy for treatment of the colitis. Last year we reported experience in 17 children, we now report colitis outcomes and lack of emergence of Vancomycin Resistant Enterococcus (VRE) in a larger, well characterised cohort of children with PSCUC receiving OVT with 2 years follow up. Methodology: Children under 18 years of age, attending the Paediatric IBD clinic at Queensland Children's Hospital, a single tertiary centre, from September 2013-December 2020 given OVT for active colitis (elevated Faecal Calprotectin (FC) and/or colonoscopy) in the context of PSC were eligible for review. PSC was confirmed by evidence of cholangiopathy, MRCP and/or Liver biopsy. Only children receiving a minimum 3 months OVT, 50mg/kg/day were included. Main indication was failed Conventional Medical Therapy (CMT). We report induction and maintenance of colitis remission. Deep Remission was defined as Paediatric Ulcerative Colitis Activity Index (PUCAI) < 10, FC < 100 +/-Mucosal Healing (MH) on colonoscopy. Stool for VRE was tested in all patients during therapy. Results: 29 children (mean age 11 years, 1-17 years;18 Male), were given OVT. Median initial treatment duration was 6 months. At 6 months: 2/29 had ongoing active colitis; 27/29 in deep remission, PUCAI < 10, normal FC < 100 (24) and/or colonoscopy (11). Of these 11, 9 had complete MH, 2 near complete MH and received a further 6 months OVT achieving complete MH. At median 12 months, 2 were lost to follow up. 20/27 were in sustained remission, most had ceased OVT and on CMT alone. 18/18 had normal FC and/or 7 had normal colonoscopy. 5/27 had relapsed and all 5 responded clinically and to normal FC after retreatment with OVT. Hence at median of 12 months follow up, 25/27 patients on the OVT program were in deep remission 22 patients had 24 months follow up but 2 had no available data. 15/22 were in complete clinical (PUCAI 0) and deep remission (normal FC,12 and/or colonoscopy, 8) and 10 of these in sustained remission, mostly off OVT. No patient required Colectomy. None developed VRE during this period. Conclusion: OVT in children with UC and confirmed PSC, mostly failing conventional medical therapy, is highly efficacious at inducing and re-inducing deep remission of colitis. No VRE was demonstrated. It is time to study OVT in formal randomized trials which also address pathogenesis to aid in the selection of patients and optimal usage within informed treatment paradigms.L6351748502021-06-08 <br />en
dc.language.isoenen
dc.relation.ispartofJournal of Pediatric Gastroenterology and Nutritionen
dc.titlePaediatric Primary Sclerosing Cholangitis-Ulcerative colitis. Audit of 2 year outcomes with oral Vancomycin treatmenten
dc.typeArticleen
dc.identifier.doi10.1097/MPG.0000000000003177en
dc.subject.keywordscontrolled studyen
dc.subject.keywordsdrug therapyen
dc.subject.keywordsfecesen
dc.subject.keywordsfollow upen
dc.subject.keywordshumanen
dc.subject.keywordslack of drug effecten
dc.subject.keywordsliver biopsyen
dc.subject.keywordsmaleen
dc.subject.keywordsnonhumanen
dc.subject.keywordsprimary sclerosing cholangitisen
dc.subject.keywordsQueenslanden
dc.subject.keywordsrandomized controlled trialen
dc.subject.keywordsremissionen
dc.subject.keywordsretreatmenten
dc.subject.keywordscolonoscopyen
dc.subject.keywordssurgeryen
dc.subject.keywordstreatment durationen
dc.subject.keywordsulcerative colitisen
dc.subject.keywordscolectomyen
dc.subject.keywordscohort analysisen
dc.subject.keywordsclinical trialen
dc.subject.keywordsclinical articleen
dc.subject.keywordsvancomycin resistant Enterococcusen
dc.subject.keywordschilden
dc.subject.keywordsvancomycinen
dc.subject.keywordscalgranulinendogenous compounden
dc.subject.keywordsschool childen
dc.subject.keywordsconference abstracten
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L635174850&from=exporthttp://dx.doi.org/10.1097/MPG.0000000000003177 |en
dc.identifier.risid533en
dc.description.pages21en
item.grantfulltextnone-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

200
checked on Apr 22, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.